Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7683742> ?p ?o }
Showing triples 1 to 99 of
99
with 100 triples per page.
- Q7683742 subject Q13240083.
- Q7683742 subject Q20927108.
- Q7683742 subject Q8760194.
- Q7683742 subject Q9068236.
- Q7683742 abstract "Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986 with $250,000, which was a large part of their family savings at that time. Both Changs grew up and received college education in chemistry in National Tsing Hua University in Taiwan and obtained Ph.D. degrees from Harvard University. For postdoctoral training, Tse Wen shifted to immunology and did research with Herman N. Eisen at the Center for Cancer Research, M.I.T.. The two Changs successively became research managers and worked with a range of monoclonal antibody projects in Centocor, Inc. based in Malvern, Pennsylvania from 1981 to 1985. The Changs were recruited by Baylor College of Medicine toward the end of 1985 and offered faculty positions in the Division of Molecular Virology. Soon after their arrival, they were encouraged by a high-ranking Baylor official and local business leaders to start a biotech venture in Houston. This was in a period of time when the economy of Houston was in slump as the result of the collapse of the oil industry.The Changs rented a corner of about 2000 square feet in a large empty warehouse building on Stella Link Road, located four miles away from the Texas Medical Center, and built laboratories. In 1987, Tanox obtained a $4 million cash infusion from the legendary biotech venture capitalist and investor, Moshe Alafi, who was a founding investor of Cetus, Amgen, Biogen, and a few other successful biotech companies. Nancy was the Chairman, President, and CEO of Tanox in its 21 year history, while Tse Wen was responsible for creating most of the company's proprietary technology and patents. Tanox's major technology was based on a series of inventions and a family of dominant patents, most notably those relating to the "anti-IgE therapy", the "migis concept", and the "anti-CεmX approach", that pertained to the use of humanized antibodies for targeting immunoglobulin E (IgE) and IgE-expressing B lymphocytes for the treatment of allergic diseases.Tanox was able to recruit a large number of talented scientists, bioengineers, and other professionals, many of whom from the Texas Medical Center. Tanox held an initial public offering and was listed in the NASDAQ in 2000. It eventually occupied the entire warehouse building and established additional R & D facilities in the adjacent land for carrying out various therapeutic antibody programs. A large number of researchers grew to be top-level research managers in pharmaceutical and large biotech companies.Tanox became the first major acquisition of Genentech in an all-cash buyout deal (US$919 million) in August 2007 (Genentech itself became wholly owned by Roche in March 2009). The acquisition of Tanox has boosted Roche/Genentech’s product pipeline substantially. In addition to the enhancement of the anti-IgE franchise by the increased rights on Xolair (omalizumab) and by the potential utility of TNX-901 (Talizumab), the other pipeline products that have gained considerable prominence include TNX-355 (Ibalizumab), a unique anti-CD4 antibody for treating AIDS, TNX-650 (Lebrikizumab), an anti-interleukin-13 antibody for treating asthma, and TNX-224, an Fab fragment of a humanized antibody against Factor D of the human immune complement system to be tested for treating geographic atrophy associated with dry age-related macular degeneration. Based on Tanox’s invention of the “anti-CεmX (also referred to anti-M1’) approach”, Genentech is developing Quilizumab, an antibody specifically targeting mIgE on B cells, for asthma and allergic diseases.".
- Q7683742 fate "acquired byGenentech(2007)".
- Q7683742 foundationPlace Q16555.
- Q7683742 foundingYear "1986".
- Q7683742 industry Q679692.
- Q7683742 keyPerson Q3908516.
- Q7683742 keyPerson Q9122598.
- Q7683742 location Q16555.
- Q7683742 location Q30.
- Q7683742 parentCompany Q899140.
- Q7683742 product Q5939625.
- Q7683742 type Q658255.
- Q7683742 wikiPageExternalLink home.asp.
- Q7683742 wikiPageWikiLink Q1053653.
- Q7683742 wikiPageWikiLink Q107988.
- Q7683742 wikiPageWikiLink Q1100474.
- Q7683742 wikiPageWikiLink Q1181835.
- Q7683742 wikiPageWikiLink Q12199.
- Q7683742 wikiPageWikiLink Q13240083.
- Q7683742 wikiPageWikiLink Q13371.
- Q7683742 wikiPageWikiLink Q140686.
- Q7683742 wikiPageWikiLink Q14878303.
- Q7683742 wikiPageWikiLink Q15787.
- Q7683742 wikiPageWikiLink Q16555.
- Q7683742 wikiPageWikiLink Q168800.
- Q7683742 wikiPageWikiLink Q176996.
- Q7683742 wikiPageWikiLink Q185142.
- Q7683742 wikiPageWikiLink Q188930.
- Q7683742 wikiPageWikiLink Q191989.
- Q7683742 wikiPageWikiLink Q1931516.
- Q7683742 wikiPageWikiLink Q204711.
- Q7683742 wikiPageWikiLink Q20927108.
- Q7683742 wikiPageWikiLink Q212646.
- Q7683742 wikiPageWikiLink Q21788706.
- Q7683742 wikiPageWikiLink Q2323511.
- Q7683742 wikiPageWikiLink Q272436.
- Q7683742 wikiPageWikiLink Q2892284.
- Q7683742 wikiPageWikiLink Q30.
- Q7683742 wikiPageWikiLink Q334848.
- Q7683742 wikiPageWikiLink Q3521441.
- Q7683742 wikiPageWikiLink Q35869.
- Q7683742 wikiPageWikiLink Q3791531.
- Q7683742 wikiPageWikiLink Q3829321.
- Q7683742 wikiPageWikiLink Q3908516.
- Q7683742 wikiPageWikiLink Q415392.
- Q7683742 wikiPageWikiLink Q417800.
- Q7683742 wikiPageWikiLink Q419458.
- Q7683742 wikiPageWikiLink Q422248.
- Q7683742 wikiPageWikiLink Q43406.
- Q7683742 wikiPageWikiLink Q458.
- Q7683742 wikiPageWikiLink Q470517.
- Q7683742 wikiPageWikiLink Q4774577.
- Q7683742 wikiPageWikiLink Q49108.
- Q7683742 wikiPageWikiLink Q507154.
- Q7683742 wikiPageWikiLink Q5439273.
- Q7683742 wikiPageWikiLink Q5939625.
- Q7683742 wikiPageWikiLink Q6060674.
- Q7683742 wikiPageWikiLink Q658255.
- Q7683742 wikiPageWikiLink Q679692.
- Q7683742 wikiPageWikiLink Q7271973.
- Q7683742 wikiPageWikiLink Q7679593.
- Q7683742 wikiPageWikiLink Q79455.
- Q7683742 wikiPageWikiLink Q79460.
- Q7683742 wikiPageWikiLink Q79848.
- Q7683742 wikiPageWikiLink Q82059.
- Q7683742 wikiPageWikiLink Q864338.
- Q7683742 wikiPageWikiLink Q864699.
- Q7683742 wikiPageWikiLink Q8760194.
- Q7683742 wikiPageWikiLink Q8839.
- Q7683742 wikiPageWikiLink Q899140.
- Q7683742 wikiPageWikiLink Q9068236.
- Q7683742 wikiPageWikiLink Q9122598.
- Q7683742 fate "acquired by Genentech".
- Q7683742 foundation "Houston, Texas".
- Q7683742 homepage home.asp.
- Q7683742 industry Q679692.
- Q7683742 keyPeople "Nancy Chang".
- Q7683742 keyPeople "Tse Wen Chang".
- Q7683742 location "Houston, Texas, US".
- Q7683742 name "Tanox".
- Q7683742 parent Q899140.
- Q7683742 products "Humanized antibody drugs".
- Q7683742 type Q658255.
- Q7683742 type Organization.
- Q7683742 type Agent.
- Q7683742 type Company.
- Q7683742 type Organisation.
- Q7683742 type Agent.
- Q7683742 type SocialPerson.
- Q7683742 type Thing.
- Q7683742 type Q43229.
- Q7683742 comment "Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986 with $250,000, which was a large part of their family savings at that time. Both Changs grew up and received college education in chemistry in National Tsing Hua University in Taiwan and obtained Ph.D. degrees from Harvard University. For postdoctoral training, Tse Wen shifted to immunology and did research with Herman N.".
- Q7683742 label "Tanox".
- Q7683742 homepage home.asp.
- Q7683742 name "Tanox".